EWA
ARCT icon

EverSource Wealth Advisors’s Arcturus Therapeutics ARCT Stock Holding History

EverSource Wealth Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93K Buy
436
+325
+293% +$2.56K ﹤0.01% 3551
2026
Q1 		$857 Buy
+111
New +$810 ﹤0.01% 3906
2025
Q4 		– Sell
-93
Closed -$1.71K – 4282
2025
Q3 		$1.71K Hold
93
– – ﹤0.01% 3568
2025
Q2 		$1.21K Buy
+93
New +$1.1K ﹤0.01% 3679

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EverSource Wealth Advisors's ARCT Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Arcturus Therapeutics (ARCT) stake by 293% in Q2 2026, buying an estimated $2.56K and bringing the position to 436 shares worth $2.93K. The position accounts for ﹤0.01% of the portfolio, ranked #3551.

EverSource Wealth Advisors first reported a position in ARCT in Q2 2025 and has held it in 4 quarters since. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • EverSource Wealth Advisors held 436 shares of Arcturus Therapeutics worth $2.93K as of Q2 2026.
  • EverSource Wealth Advisors bought 325 Arcturus Therapeutics shares in Q2 2026, an estimated $2.56K.
  • Arcturus Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3551 holding.
  • EverSource Wealth Advisors first reported a position in Arcturus Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.